Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort
Rheumatology International · 13.05.2026 · 46 (6)
DOI: 10.1007/s00296-026-06119-y ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Rheumatology International, online erschienen am 13.05.2026. Verfasst von Nelly Ziade und 12 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Saint-Joseph University, Beirut, Lebanon. nelly.zoghbi@usj.edu.lb. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products, Healthcare Disparities. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Despite improvement in treatment, rheumatoid arthritis (RA) management remains inconsistent. AIMS: To evaluate the worldwide disparities in the use of biological and targeted molecules (advanced) RA therapies, focusing on differences across continents and socioeconomic strata, and to identify factors associated with their utilisation. METHODS: Cross-sectional analysis of the international COVAD-2 cohort, including demographics, socioeconomic factors, disease characteristics, patient-reported outcomes, and treatments. Primary outcomes assessed treatment distribution by continent, secondary outcomes evaluated distribution by Human Development Index (HDI), with predictors analysed using multivariable logistic regression. RESULTS: At the time of analysis, COVAD2 included 10,739 participants; 2007 had RA, 1997 with geographical data included in this study (mean age 50.9 years, 88.1% women). Most patients came from Europe (39.4%) and Asia (24.8%); 61.3% and 23.7% were from very high- and high-HDI countries, respectively. Overall, 29.6% of patients used advanced therapies, with the highest rate in Europe (44.0%), followed by North America and Oceania (33.9%), South America (31.1%), Asia (11.7%), and Africa (5.3%) (p < 0.001). Usage correlated strongly with HDI: 2.7% in low-HDI to 38.8% in very-high-HDI countries (Compared to very-high income, Odds Ratio for high 0.561 (95% CI 0.403;0.782), for medium 0.288 (95% CI 0.153;0.539), and for low income 0.275 (95% CI 0.034;2.199); p < 0.001). Regions with limited access relied more on glucocorticoids. Disparities across continents and HDI categories remained after adjusting for confounders(demographic characteristics, disease activity, comorbidities, and patient-reported outcomes. CONCLUSION: Marked continent- and HDI-based inequities in biologic and targeted DMARD use persist globally, demanding coordinated action from the rheumatology community to ensure equitable RA care across resource settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology, Saint-Joseph University, Beirut, Lebanon. nelly.zoghbi@usj.edu.lb.
- Rheumatology, Hotel-Dieu de France Hospital, 6th floor, Tour des Consultations Externes, Alfred Naccache Blvd. Achrafieh, Beirut, Lebanon. nelly.zoghbi@usj.edu.lb.
- Faculty of Medicine, Health Sciences Research Center (CReSS), International University of Rabat (UIR), Rabat, Morocco.
- Temara Provincial Hospital, Temara, Morocco.
- Rheumatology, Saint-Joseph University, Beirut, Lebanon.
- Maharashtra Institute of Medical Sciences and Research, Latur, Maharashtra, India.
Zitieren
APA
Ziade, N., Hmamouchi, I., Moussallem, M., Salameh, B. L., Yaadav, P., Makol, A., Milchert, M., Velikova, T., Parodis, I., Nikiphorou, E., Agarwal, V., Gupta, L., & COVAD Study Group (2026). Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort. Rheumatology International, 46(6). https://doi.org/10.1007/s00296-026-06119-y
Vancouver
Ziade N, Hmamouchi I, Moussallem M, Salameh BL, Yaadav P, Makol A, et al. Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort. Rheumatology International. 2026;46(6). doi:10.1007/s00296-026-06119-y
BibTeX
@article{Ziade2026,
author = {Ziade, Nelly and Hmamouchi, Ihsane and Moussallem, Marc and Salameh, Bendy Lemon and Yaadav, Praggya and Makol, Ashima and Milchert, Marcin and Velikova, Tsvetelina and Parodis, Ioannis and Nikiphorou, Elena and Agarwal, Vikas and Gupta, Latika and COVAD Study Group, COVAD Study Group},
title = {Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort},
journal = {Rheumatology International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1007/s00296-026-06119-y}
}
EUVIMED